2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
211
Triple Negative Breast Neoplasms
32
Stomach Neoplasms
32
Inflammatory Breast Neoplasms
21
Esophageal Neoplasms
16
Carcinoma, Hepatocellular
15
Lymphoma, Large B-Cell, Diffuse
9
Sarcoma
8
Neoplasms
8
Non-Muscle Invasive Bladder Neoplasms
6
Urinary Bladder Neoplasms
5
Pancreatic Neoplasms
5
Liver Neoplasms
5
Breast Neoplasms, Male
5
Adenocarcinoma Of Esophagus
5
Ovarian Neoplasms
4
Lymphoma
4
Testicular Neoplasms
3
Primary Breast Cancer
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pathologic Complete Response
3
Hemangiosarcoma
3
Gallbladder Neoplasms
3
Carcinoma, Ductal, Breast
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Recurrence
2
Prostatic Neoplasms
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neoplastic Cells, Circulating
2
Interventions
olaparib
1
niraparib
1
fluzoparib
1
Vernalization
1
Standard of Care
1
Poly(ADP-ribose) Polymerase Inhibitors
1
Irinotecan
1
Epirubicin
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kenny-Caffey syndrome, Type 1
×
Epirubicin
×
Clear all
NCT02789332
2020-03-17
GeparOla
GBG Forschungs GmbH
Phase 2
Completed
107 enrolled